advertisement
14 Costing studies; pharmacoeconomics (6)
Showing records 1 to 6
Display all abstracts in classification 14 Costing studies; pharmacoeconomics
Search within classification 14 Costing studies; pharmacoeconomics25841 Cost benefit analysis of bimatoprost compared with other prostaglandin analogues in patients with primary open angle glaucoma (POAG) in the United States: A payer's perspective
Berenson K; Arora S; Kymes S; Hollander DA; Fiscella R; Burk C; Patel V
Journal of Managed Care Pharmacy 2010; 16: 146
26119 Treatment of Glaucoma in Clinical Practice: Four-year Results From a Patient Registry in France
Kobelt G; Texier-Richard B; Buchholz P; Bron A; Renard JP; Rouland JF; Nordmann JP
Journal of Glaucoma 2010; 19: 199-206
26223 Effect of patient's life expectancy on the cost-effectiveness of treatment for ocular hypertension
Kymes SM; Plotzke MR; Kass MA; Boland MV; Gordon MO
Archives of Ophthalmology 2010; 128: 613-618
25823 Epidemiology of glaucoma and drug utilization in UK primary care
Maguire A; Thompson M
Pharmacoepidemiology and Drug Safety 2009; 18: S143
25891 First-year treatment costs among new initiators of topical prostaglandin analogs: Pooled results
Schmier JK; Covert DW
Clinical Ophthalmology 2010; 4: 437-445
26228 Hospital-based glaucoma clinics: what are the costs to patients?
Sharma A; Jofre-Bonet M; Panca M; Lawrenson JG; Murdoch I
Eye 2010; 24: 999-1005
